Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19873467 | 0.91 | ACP1 (0.40) | CHRM3ACP1NMT1ACKR3HRH2 | |
| SCHEMBL16928032 | 0.91 | CAMK2D (0.44) | CHRM3ACP1NMT1CHRNB1CHRNB2 | |
| SCHEMBL16928575 | 0.91 | KDM1A (0.45) | ACP1NMT1CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL16928309 | 0.90 | ACP1 (0.47) | CHRM3ACP1NMT1CHRNB1CHRNB2 | |
| SCHEMBL16928011 | 0.90 | ACP1 (0.48) | CHRM3ACP1NMT1ACKR3HRH2 | |
| SCHEMBL17721591 | 0.89 | ACP1 (0.39) | ACP1NMT1CHRNB2ACKR3HRH2 | |
| SCHEMBL16928030 | 0.89 | CHRM3 (0.42) | CHRM3ACP1NMT1ACKR3HRH2 | |
| SCHEMBL17721587 | 0.88 | ACP1 (0.38) | CHRM3ACP1NMT1ACKR3HRH2 | |
| SCHEMBL17721574 | 0.87 | PTGS2 (0.39) | ACP1NMT1ACKR3HRH2HRH1 | |
| SCHEMBL19873462 | 0.86 | CAMK2D (0.48) | CHRM3ACP1NMT1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970153-B1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE US SECRETARY OF THE ARMY ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2018-02-21 | — | — | EP | claimed |
| US-9334246-B2 | Substituted triazines for malaria treatment and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2016-05-10 | — | — | US | claimed |
| EP-3351538-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | The United States of America, as represented by The Secretary of The Army, on behalf of Walter Reed Army Institute of Research (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2970153-B1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE US SECRETARY OF THE ARMY ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9700562-B2 | Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | WALTER REED ARMY INST OF RES THE USA AS REPRESENTED BY THE SEC OF THE ARMY ON BEHALF OF THE (US) | 2016-07-28 | — | — | US | disclosed |
| US-9334246-B2 | Substituted triazines for malaria treatment and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | CYP3A5, HCCS, COX15 | CHRM3 2635/4885ACP1 4253/4885NMT1 912/4885 |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | HCCS, CYP3A5, COX15 | CHRM3 2962/4885ACP1 4108/4885NMT1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.